Byung-In Moon

Byung-In Moon


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
ALAnbok Lee
Anbok Lee
BMByung-In Moon
Byung-In Moon
TKTae Hyun Kim
Tae Hyun Kim
Lee A, et al. Ann Lab Med. 2020 Mar;40(2):114-121. https://doi.org/10.3343/alm.2020.40.2.114

1 January 2011 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
CYCha Kyong Yom
Cha Kyong Yom
WHWonshik Han
Wonshik Han
SKSung-Won Kim
Sung-Won Kim
HKHee Sung Kim
Hee Sung Kim
HSHee-Chul Shin
Hee-Chul Shin
BMByung-In Moon
Byung-In Moon
Yom CK, et al. J Breast Cancer. 2011 Dec;14(4):262-268. https://doi.org/10.4048/jbc.2011.14.4.262

Verified
Journal Article
Open access
PDF file
JAJeongshin An
Jeongshin An
HKHyungju Kwon
Hyungju Kwon
WLWoosung Lim
Woosung Lim
BMByung-In Moon
Byung-In Moon
The microbiome involved in the human estrogen metabolism is known as the estrobolome. This study aimed to show that the estrobolome can be used in breast cancer treatment. We first analyzed the blood microbiome composition of healthy controls and patients with breast cancer. In particular, we investigated the bacteria producing β−glucuronidase and/or β−galactosidase, which are involved in estrogen metabolism in the human body. Staphylococcus species were more abundant in healthy controls than in breast cancer patients and therefore were selected for further analyses. The effect of Staphylococcus aureus on endocrine therapy was analyzed by a combination treatment with tamoxifen. Analysis of the microbiome of blood samples showed that species producing β−glucuronidase were more abundant in breast cancer patients than in healthy controls. Further experiments confirmed that the efficacy of tamoxifen increased when administered in conjugation with the extracellular vesicles (EVs) of S. aureus. Based on our results, we deduced that S. aureus EVs could potentially be used as adjuvants for breast cancer treatment in the future.

13 October 2016 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
HJHyejung Jung
Hyejung Jung
BKBomin Kim
Bomin Kim
BMByung-In Moon
Byung-In Moon
Eok-Soo OhEok-Soo Oh
Eok-Soo Oh

1 January 2017 in Journal of Cancer
Verified
Journal Article
Open access
SKSewha Kim
Sewha Kim
SPSanghui Park
Sanghui Park
MCMin Sun Cho
Min Sun Cho
WLWoosung Lim
Woosung Lim
BMByung-In Moon
Byung-In Moon
SSSun Hee Sung
Sun Hee Sung
Indoleamine 2,3-dioxygenase 1 (IDO1) is an immunosuppressive enzyme involved in tumor immune escape. Blockade of the IDO1 pathway is an emerging modality of cancer immunotherapy. Triple-negative breast cancer (TNBC) lacks established therapeutic targets and may be a good candidate for this novel immunotherapeutic agent. The purpose of this study was to evaluate the clinicopathologic characteristics of the IDO1-expressing TNBC subset. A tissue microarray was constructed from 200 patients with TNBC. Immunohistochemistry (IHC) for IDO1 and TNBC molecular subtype-surrogate markers (AR, GCDFP-15, claudin-3, E-cadherin, CK5/6, and EGFR) was performed using this tissue microarray. Real-time polymerase chain reaction was performed to confirm the IDO1 mRNA expression level in 16 fresh-frozen TNBC samples. Two hundred TNBCs were classified into four subtypes based on surrogate IHC results: 22 luminal androgen receptor type (11.0%), 23 claudin-low type (11.4%), 103 basal-like type (51.5%), and 52 mixed type (26.0%). IDO1 positivity (defined as expression of >10% tumor cells) was observed in 37% of all TNBCs. IDO1 IHC expression was well correlated with mRNA expression. IDO1 positivity was significantly associated with smaller tumor size, dense stromal lymphocytic infiltration, and basal-like phenotype; however, it did not affect the patients' prognosis. IDO1 expression in basal-like TNBCs is considered an immune inhibitory signal that counterbalances active immunity and may reflect the high mutational load of these tumors. Our results suggest which patients with TNBC would be more efficaciously treated with IDO1 blockade.

29 March 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JAJeongshin An
Jeongshin An
JYJinho Yang
Jinho Yang
HKHyungju Kwon
Hyungju Kwon
WLWoosung Lim
Woosung Lim
YKYoon-Keun Kim
Yoon-Keun Kim
BMByung-In Moon
Byung-In Moon
The incidence of breast cancer (BC) is increasing in South Korea, and diet is closely related to the high prevalence of BC. The microbiome directly reflects eating habits. In this study, a diagnostic algorithm was developed by analyzing the microbiome patterns of BC. Blood samples were collected from 96 patients with BC and 192 healthy controls. Bacterial extracellular vesicles (EVs) were collected from each blood sample, and next-generation sequencing (NGS) of bacterial EVs was performed. Microbiome analysis of patients with BC and healthy controls identified significantly higher bacterial abundances using EVs in each group and confirmed the receiver operating characteristic (ROC) curves. Using this algorithm, animal experiments were performed to determine which foods affect EV composition. Compared to BC and healthy controls, statistically significant bacterial EVs were selected from both groups, and a receiver operating characteristic (ROC) curve was drawn with a sensitivity of 96.4%, specificity of 100%, and accuracy of 99.6% based on the machine learning method. This algorithm is expected to be applicable to medical practice, such as in health checkup centers. In addition, the results obtained from animal experiments are expected to select and apply foods that have a positive effect on patients with BC.